Clinical Trial Update: Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating temozolomide and irinotecan with or without bevacizumab in young patients with recurrent or refractory medulloblastoma or CNS primitive…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Neoplasm
• Medulloblastoma
• Pineoblastoma
• Primitive Neuroectodermal Tumor

Drugs mentioned

• Bevacizumab (bevacizumab)
• IRINOTECAN HYDROCHLORIDE (irinotecan hydrochloride)
• Temozolomide (Temozolomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Central Nervous System Neoplasm, Pineoblastoma | Phase 2 | Status: COMPLETED | Results posted: 2019-09-13